Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Current Price
$37.48
-2.29%GoodMoat Value
$101.41
170.6% undervaluedAlkermes plc (ALKS) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Alkermes plc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $1.56B. Gross profit (TTM) is $1.35B. EBITDA is $276.38M. Earnings per share (EPS) is $1.43. The P/E ratio is 40.90. Market capitalization is $6.25B.
Free cash flow (FCF) is $483.13M. EPS growth CAGR is -17.58%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Alkermes plc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
